Medtronic announced late-breaking clinical data from the STROKE AF clinical study, which the company said "showed large and small vessel disease stroke patients had a 10-fold increase in AF detection with the Reveal LINQ insertable cardiac monitor, ICM, at three years compared to patients randomized to standard of care who did not receive continuous, long-term monitoring." The latest results, presented today as a late-breaking clinical trial at the American Stroke Association’s International Stroke Conference 2023, "build on the STROKE AF study 12-month primary endpoint results published in JAMA in June 2021," the company stated.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Bernstein medical tech/devices analysts hold analyst/industry conference call
- Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
- Medtronic recalls Hemodialysis Catheters for leaks, FDA says
- Orchestra BioMed begins trading on Nasdaq with cash runway into 2026
- Medtronic recommends rejection of below-market mini-tender by TRC Capital
